SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-004144
Filing Date
2023-01-20
Accepted
2023-01-20 16:34:58
Documents
8
Period of Report
2023-01-20

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea171919-6k_xtlbiopharma.htm 6-K 15302
2 NOTICE AND PROXY STATEMENT WITH RESPECT TO THE COMPANY'S ANNUAL GENERAL MEETING ea171919ex99-1_xtlbiopharma.htm EX-99.1 107925
3 PROXY CARD FOR HOLDERS OF ORDINARY SHARES WITH RESPECT TO THE COMPANY'S ANNUAL G ea171919ex99-2_xtlbiopharma.htm EX-99.2 28259
4 VOTING INSTRUCTION CARD FOR AMERICAN DEPOSITARY SHARE HOLDERS WITH RESPECT TO TH ea171919ex99-3_xtlbiopharma.htm EX-99.3 1796
5 GRAPHIC ex99-1_001.jpg GRAPHIC 3192
6 GRAPHIC ex99-2_001.jpg GRAPHIC 3192
7 GRAPHIC image_004.jpg GRAPHIC 112235
8 GRAPHIC image_003.jpg GRAPHIC 99980
  Complete submission text file 0001213900-23-004144.txt   455804
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-36000 | Film No.: 23541476
SIC: 2834 Pharmaceutical Preparations